Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VinCaT: Vinorelbine, Carboplatin, and Trastuzumab in HER2+ Metastatic Breast Cancer
NCT00431704Phase 2Unknown
- Sponsor
- National Cancer Institute
- Start
- Oct 2007
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of vinorelbine, carboplatin and trastuzumab in breast cancer and HER2-positive breast cancer, sponsored by National Cancer Institute. Status: unknown.
02
Drugs
03
Conditions
breast cancerHER2-positive breast cancer
Beyond the preview
Go deeper on NCT00431704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431704.